B
Bull
Bull · 25%MNMD
$8.82
情境價格
$15.020
+0.152 (+1.01%)收盤時
Loading chart…
- High
- 15.160
- Open
- 14.860
- VWAP
- 14.83
- Vol
- 2.06M
- Mkt Cap
- 521.08M
- Low
- 14.310
- Amount
- 30.58M
- EV/EBITDA, TTM
- -5.92
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
估值指標
The current forward P/E ratio for Definium Therapeutics Inc (MNMD) is -7.41, compared to its 5-year average forward P/E of -4.67.
Alphio AI Price Scenarios for MNMD
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding MNMD
事件時間軸
資訊
5.001-29Yahoo FinanceDefinium Appoints Roger Adsett to Board of Directors to Drive Growth
6.012-23SeekingAlphaJones Initiates Coverage on MindMed, Highlighting Potential of Psychedelics for Mental Health Treatment
8.012-19SeekingAlphaPsychedelic Stocks May Gain from Marijuana Rescheduling, According to Jefferies
- 1.012-18Businesswire
MindMed CEO to Present at J.P. Morgan Healthcare Conference on January 14, 2026
- 5.012-15Newsfilter
MindMed Grants 31,500 Stock Options to New Employees
MNMD FAQ — answered by Alphio AI
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD). It operates in the Healthcare sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。